Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 15/20 | 0.56 |
| ▸ | SSTR5 | P35346 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MLNR | O43193 | 1/20 | 0.45 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.45 |
| ▸ | EED | O75530 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HLA-A | P04439 | 1/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12046435 | 0.88 | SSTR5 (0.64) | P2RX3SSTR5KCNH2MEN1MLNR | |
| SCHEMBL12046388 | 0.77 | P2RX3 (0.83) | P2RX3 | |
| SCHEMBL10529762 | 0.76 | SSTR5 (0.78) | SSTR5KCNH2MEN1MLNRCACNA1F | |
| SCHEMBL12045840 | 0.75 | P2RX3 (0.62) | P2RX3 | |
| SCHEMBL4635524 | 0.75 | SSTR5 (0.44) | SSTR5KCNH2MEN1MLNRCACNA1F | |
| SCHEMBL10056858 | 0.74 | P2RX3 (0.74) | P2RX3 | |
| SCHEMBL11480609 | 0.74 | SSTR5 (0.57) | SSTR5KCNH2MEN1MLNRCACNA1F | |
| SCHEMBL12046390 | 0.73 | P2RX3 (0.77) | P2RX3 | |
| SCHEMBL10056851 | 0.73 | P2RX3 (0.68) | P2RX3 | |
| SCHEMBL17590244 | 0.73 | P2RX3 (0.76) | P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718790-B2 | Triazine derivative and pharmaceutical composition having an analgesic activity comprising the same | SHIONOGI & CO., LTD. (JP) | 2017-08-01 | — | — | US | disclosed |
| US-9718790-B2 | Triazine derivative and pharmaceutical composition having an analgesic activity comprising the same | SHIONOGI & CO., LTD. (JP) | 2017-08-01 | — | — | US | disclosed |
| US-9688643-B2 | Triazine derivative and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2017-06-27 | — | — | US | disclosed |
| US-9688643-B2 | Triazine derivative and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2017-06-27 | — | — | US | disclosed |
| US-20160185736-A1 | NOVEL, TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. | 2016-06-30 | — | — | US | disclosed |
| US-20160185736-A1 | NOVEL, TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. | 2016-06-30 | — | — | US | disclosed |
| US-9150546-B2 | Triazine derivative and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| US-9150546-B2 | Triazine derivative and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| WO-2012020749-A1 | TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOUND THAT CONTAINS SAME AND EXHIBITS ANALGESIC ACTIVITY | 塩野義製薬株式会社 (JP) | 2012-02-16 | — | — | WO | disclosed |
| US-20110319414-A1 | NOVEL TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319414-A1 | NOVEL TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185736-A1 | NOVEL, TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | P2RX3, P2RX5, P2RX2 | P2RX3 1/4885SSTR5 397/4885KCNH2 283/4885 |
| US-20110319414-A1 | NOVEL TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | P2RX3, P2RX5, P2RX2 | P2RX3 1/4885SSTR5 499/4885KCNH2 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.